Arsenic Trioxide and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia
Completed · Phase 1/Phase 2
Conditions studied: Leukemia
In brief
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Imatinib mesylate may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. Combining chemotherapy with imatinib mesylate may kill more cancer cells. PURPOSE: Phase I/II trial to study the effectiveness of combining arsenic trioxide with imatinib mesylate in treating patients who have chronic phase chronic myelogenous leukemia.
Key facts
- Study ID
- NCT00053248
- Run by
- OHSU Knight Cancer Institute
- People needed
- 16
- Starts
- 2002-10-01
- Expected to finish
- 2005-06-01
- Last updated by the study team
- 2012-05-28
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UCLA Department of Medicine, Division of Hematology/Oncology — Los Angeles, California, United States
- H. Lee Moffitt Cancer Center — Tampa, Florida, United States
- OHSU Knight Cancer Institute — Portland, Oregon, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.